Hudson Bay Capital Management
SLNOW

Hudson Bay Capital Management’s Soleno Therapeutics, Inc. Series A Warrant SLNOW Stock Holding History

Hudson Bay Capital Management’s Portfolio SLNOW Stock Details SLNOW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,000
Closed -$4K – 607
2017
Q3 		$4K Hold
6,000
– – ﹤0.01% 364
2017
Q2 		$5K Buy
+6,000
New +$5.5K ﹤0.01% 509

Other funds holding SLNOW

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hudson Bay Capital Management's SLNOW Position: Q4 2017 in Review

Hudson Bay Capital Management sold out of Soleno Therapeutics, Inc. Series A Warrant (SLNOW) in Q4 2017, closing a stake of 6,000 shares — an estimated $4K sold.

Hudson Bay Capital Management first reported a position in SLNOW in Q2 2017 and held it in 2 quarters. The position peaked at $5K in Q2 2017. 3 funds tracked by Wall St. Rank hold SLNOW as of Q4 2017.

  • Hudson Bay Capital Management reported no remaining Soleno Therapeutics, Inc. Series A Warrant position as of Q4 2017 after selling out during the quarter.
  • Hudson Bay Capital Management sold 6,000 Soleno Therapeutics, Inc. Series A Warrant shares in Q4 2017, an estimated $4K.
  • Hudson Bay Capital Management first reported a position in Soleno Therapeutics, Inc. Series A Warrant in Q2 2017 and held it in 2 quarters.
  • Hudson Bay Capital Management's Soleno Therapeutics, Inc. Series A Warrant position peaked at $5K in Q2 2017.
  • 3 funds tracked by Wall St. Rank held Soleno Therapeutics, Inc. Series A Warrant as of Q4 2017.

Based on Hudson Bay Capital Management's 13F filing for Q4 2017, filed 12 Feb 2018.